TMB-2

Todos Medical to Present at the RHK 2022 Disruptive Growth Conference

Retrieved on: 
Tuesday, December 6, 2022
TMB-2, Conference, Lymphocyte, TBIA, Monocyte, Cell cycle, Biotechnology, Knowledge, Legislation, Pressure, Cancer prevention, Synthase, PCR, Neurodegeneration, Neuron, Alzheimer's disease, OTCQB, Immune system, Plasma, Research, Apoptosis, Severe acute respiratory syndrome coronavirus 2, Cancer, Brain, Amazon, Medical imaging, Pharmaceutical industry, Pharma

New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be presenting at the RHK 2022 Disruptive Growth Conference on Tuesday, December 6th at 12:20pm ET.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be presenting at the RHK 2022 Disruptive Growth Conference on Tuesday, December 6th at 12:20pm ET.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, HRV, Patient, Cancer prevention, Combination, Immune system, Cancer, Knowledge, Brain, Biotechnology, Neurodegeneration, Monocyte, Legislation, Amazon, Apoptosis, TBIA, PCR, TMB-2, Synthase, Trial, Alzheimer's disease, Research, OTCQB, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, Cell cycle, Neuron, Pressure, Plasma, Pharmaceutical industry, Medical imaging, Pharma

New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at World Antiviral Congress 2022 .

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at World Antiviral Congress 2022 .
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL proteasebased diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses.
  • 3CL Pharma, through Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir, while also developing the 3CL protease diagnostic TolloTest.

Todos Medical to Attend World Antiviral Congress

Retrieved on: 
Tuesday, November 22, 2022
Cancer prevention, Immune system, Cancer, Knowledge, Brain, Biotechnology, Neurodegeneration, Monocyte, Legislation, Amazon, Apoptosis, TBIA, PCR, TMB-2, Synthase, Alzheimer's disease, Research, OTCQB, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, Cell cycle, Neuron, Pressure, Plasma, Pharmaceutical industry, Medical imaging, Pharma

New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022 .

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022 .
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical Announces Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022
CFO, CBN, Risk, EUA, Brain, Legislation, COVID-19 policy of the Joe Biden administration, Apoptosis, Dietary supplement, TMB-2, Synthase, Severe acute respiratory syndrome coronavirus 2, Neuron, Immune system, B cell, Patient, COVID, Lymphocyte, Trial of the century, Pressure, Plasma, COVID-19, Cancer immunotherapy, Public health, Cancer, Physician, Neurodegeneration, Monocyte, Amazon, IRB, TBIA, Alzheimer's disease, Research, OTCQB, Cell cycle, Knowledge, Biotechnology, Aerospace, CLIA, PCR, CBG, Memory, Emergency Use Authorization, Diagnosis, Natural killer T cell, Pharmaceutical industry, Vaccine, Video game, Medical imaging, Long COVID, CBD, Pharma

New York, NY, and Tel Aviv, ISRAEL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the third quarter of 2022, which ended on September 30, 2022. The Company will host a conference call today at 8:30am ET on November 15, 2022.

Key Points: 
  • In the second quarter of 2022, 3CL Pharma announced positive biomarker data stemming from a positive clinical Phase 2 clinical study initially reported in January 2022.
  • In the second quarter of 2022, the Company received an IRB waiver to conduct a market research study on customer experience using Tollovid.
  • Revenues: Total revenue in the third quarter of 2022 was$1.914 million, as compared to revenue of $1,010,000in the third quarter of 2021.
  • Loss from Operations: The Company recorded an operating loss of$(1,802,000)in the third quarter of 2022 compared to an operating loss of$(2,497,000)in the third quarter of 2021.

Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022

Retrieved on: 
Monday, November 14, 2022
Cancer prevention, Immune system, Cancer, Knowledge, Brain, Biotechnology, Neurodegeneration, Monocyte, Legislation, Amazon, Apoptosis, TBIA, PCR, TMB-2, Synthase, Alzheimer's disease, Research, OTCQB, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, Cell cycle, Neuron, Pressure, Plasma, Medical imaging, Pharmaceutical industry, Pharma

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.

Key Points: 
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Lymphocyte, Cell cycle, Plasma, Marketing, Method, PCR, Amazon, Severe acute respiratory syndrome coronavirus 2, Knowledge, Research, Technology, TMB-2, TBIA, Neuron, Legislation, Cancer, Monocyte, Brain, Solution, Pressure, U.S. Securities and Exchange Commission, Synthase, Cancer immunotherapy, Neurodegeneration, Company, OTCQB, Alzheimer's disease, Biotechnology, Immune system, Apoptosis, Pharmaceutical industry, Medical imaging, Pharma

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.

Key Points: 
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe.
  • Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical Announces BioFuture™ NYC 2022 Presentation

Retrieved on: 
Friday, November 4, 2022
Amazon, Severe acute respiratory syndrome coronavirus 2, Company, Neurodegeneration, Research, TBIA, PCR, Cell cycle, Biotechnology, Apoptosis, GLOBE, Alzheimer's disease, Method, Legislation, Brain, Knowledge, TMB-2, Plasma, Cancer prevention, Neuron, OTCQB, U.S. Securities and Exchange Commission, Cancer, Pressure, Immune system, Technology, Lymphocyte, Monocyte, Synthase, Solution, Medical imaging, Pharmaceutical industry, Pharma

New York, NY, and Tel Aviv, ISRAEL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be making a corporate presentation and providing a corporate update to the investment community at BioFuture NYC 2022 on Tuesday November 8th, 2022 at 3:30 pm.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be making a corporate presentation and providing a corporate update to the investment community at BioFuture NYC 2022 on Tuesday November 8th, 2022 at 3:30 pm.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA

Retrieved on: 
Friday, October 14, 2022
Pressure, Method, U.S. Securities and Exchange Commission, TMB-2, Neurodegeneration, US Foods, Biotechnology, LDT, Research, Monocyte, Cancer prevention, Cancer, PCR, EUA, Technology, Knowledge, Infection, Synthase, Immune system, Neuron, Company, Emergency Use Authorization, Legislation, Alzheimer's disease, CEO, GLOBE, Amazon, Brain, Plasma, TBIA, Medicine, Monkeypox, Cell cycle, FDA, Apoptosis, OTCQB, Solution, Lymphocyte, Pharmaceutical industry, Medical imaging, Pharma

The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 0.95 viral copies per reaction (0.095 copies/ul).

Key Points: 
  • The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 0.95 viral copies per reaction (0.095 copies/ul).
  • The submission of this EUA application underscores our commitment to providing best-in-class PCR-based testing for emerging infectious diseases, said Gerald E. Commissiong, President & CEO of Todos Medical and Provista.
  • Regulatory changes at FDA have forced us to only be able to offer lesion-based PCR testing.
  • As we conduct more research and work with the agency, we are hopeful to be able to submit an EUA for saliva-based PCR testing for MonkeyPox in the future.

Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics

Retrieved on: 
Thursday, October 6, 2022
Method, Public relations, COVID, Monocyte, PCR, RP, Legislation, CEO, Sexually transmitted infection, Amazon, TBIA, Cell cycle, Solution, Cancer, Lymphocyte, STI, TMB-2, Neurodegeneration, Accountable care organization, Knowledge, Company, CyberGraphX, GLOBE, TEL, Pathology, Research, Collection, Technology, Alzheimer's disease, Urinary tract infection, Monkeypox, Apoptosis, OTCQB, Pressure, Physician, U.S. Securities and Exchange Commission, Quest Diagnostics, Biotechnology, Cancer prevention, UTI, Synthase, Immune system, Neuron, Acquisition, Brain, Plasma, Pharmaceutical industry, Medical imaging, Pharma, Long COVID

NEW YORK, NY and TEL AVIV, Israel, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP laboratory, Provista Diagnostics , has successfully completed a pilot launch of the Companys Suite of PCR Testing services in the rural city of Dunnellon, Florida.

Key Points: 
  • NEW YORK, NY and TEL AVIV, Israel, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP laboratory, Provista Diagnostics , has successfully completed a pilot launch of the Companys Suite of PCR Testing services in the rural city of Dunnellon, Florida.
  • The PCR testing services include Urinary Tract Infection (UTI), Wound, Respiratory Pathogen (RP), Gastrointestinal (GI), Sexually Transmitted Infections (STI), COVID and MonkeyPox panels.
  • Provista has now officially expanded beyond COVID testing and is beginning to generate an increasing part of its revenue from non-COVID related testing, said Gerald Commissiong, President & CEO of Provista Diagnostics and Todos Medical, Provistas parent company.
  • Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics , Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Pane l analyses, and Provista's proprietary commercial-stage Videssa breast cancer blood test.

Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform

Retrieved on: 
Friday, September 30, 2022
Apoptosis, Plasma, Cancer biomarker, FTIR, Brain, FDA, Liquid biopsy, Synthase, Cancer, U.S. Securities and Exchange Commission, Legislation, Knowledge, Company, OTCQB, Growth, Pressure, Lymphocyte, USD, Patient, Breast cancer, CEO, USPTO, Technology, Solution, TMB-2, TBIA, Notice, PCR, Method, Biotechnology, Research, Monocyte, Cell cycle, GLOBE, Amazon, Immune system, Patent, Neurodegeneration, Geology applications of Fourier transform infrared spectroscopy, Neuron, Alzheimer's disease, CAGR, Medical imaging, Pharmaceutical industry, Infrared, Pharma

The Notices of Allowance are for patent applications entitled 1) Infrared (IR) Spectroscopy System and 2) Infrared Analysis of Benign Tumors.

Key Points: 
  • The Notices of Allowance are for patent applications entitled 1) Infrared (IR) Spectroscopy System and 2) Infrared Analysis of Benign Tumors.
  • The Company has already received CE marks for its TBIA blood diagnostic test in breast cancer and colon cancer.
  • The global cancer diagnostics market is expected to experience growth at a CAGR of 8.4% over the forecast period 2022 to 2030.
  • Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.